Experts reassess endpoints, patient selection, targets, and timing for the development of successful immune-based treatments ...

WALTHAM, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology ...

Vividion Therapeutics, Inc., a clinical-stage biopharmaceutical company, and a wholly owned and independently operated ...

Vividion Therapeutics secures worldwide rights to develop & commercialize clinical-stage WRN covalent inhibitor, VVD-214: San Diego, California Friday, June 6, 2025, 11:00 Hrs [IS ...

Vividion Therapeutics, Inc. (Vividion), a clinical-stage biopharmaceutical company, and a wholly owned and independently ...

Vividion Therapeutics and Bayer are advancing VVD-214, the world’s only clinical-stage covalent WRN inhibitor, for MSI-high ...

Officially completing its acquisition of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT), Sun Pharmaceutical Industries Ltd. has ...

Checkpoint Therapeutics, Inc. ("Checkpoint"), has been acquired by Sun Pharmaceutical Industries Limited (together with its subsidiaries and/or associated companies, "Sun Pharma"). The transaction ...

The acquisition of Checkpoint Therapeutics by Sun Pharmaceutical ... Fortress aims to further advance its pipeline and focus on new business development opportunities, including potential FDA ...